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Mounting evidence demonstrates that kynurenine metabolism may play an important 
pathogenic role in the development of multiple neurological and neuropsychiatric 
disorders. The kynurenine pathway consists of two functionally distinct branches 
that generate both neuroactive and oxidatively reactive metabolites. In the brain, the 
rate-limiting enzyme for one of these branches, kynurenine 3-monooxygenase (KMO), is 
predominantly expressed in microglia and has emerged as a pivotal point of metabolic 
regulation. KMO substrate and expression levels are upregulated by pro-inflammatory 
cytokines and altered by functional genetic mutations. Increased KMO metabolism 
results in the formation of metabolites that activate glutamate receptors and elevate 
oxidative stress, while recent evidence has revealed neurodevelopmental consequences 
of reduced KMO activity. Together, the evidence suggests that KMO is positioned at 
a critical metabolic junction to influence the development or trajectory of a myriad of 
neurological diseases. Understanding the mechanism(s) by which alterations in KMO 
activity are able to impair neuronal function, and viability will enhance our knowledge of 
related disease pathology and provide insight into novel therapeutic opportunities. This 
review will discuss the influence of KMO on brain kynurenine metabolism and the current 
understanding of molecular mechanisms by which altered KMO activity may contribute 
to neurodevelopment, neurodegenerative, and neuropsychiatric diseases.
Keywords: neuroinflammation, kynurenine 3-monooxygenase, kynurenine pathway, microglia, neurodevelopmental 
disorders, neurodegenerative diseases, neuropsychiatric disorders
introduction
During healthy conditions, most dietary tryptophan is metabolized in the liver to generate nicotinic 
acid and subsequent energy-producing co-factors through the kynurenine metabolic pathway (1). 
Kynurenine metabolites were first identified in urinary excretions, and the observation of a cor-
relation between the disruption of dietary tryptophan metabolism and neuropsychiatric diseases 
sparked an interest in the potential pathogenic role of kynurenines (2, 3). Identification of receptor 
targets within the brain provided a putative mechanistic role for kynurenine metabolites in disor-
ders of the central nervous system. The kynurenine pathway (Figure 1) diverges along two main 
metabolic branches that produce metabolites, kynurenic acid (KA), and quinolinic acid (QA), that 
both bind to the N-methyl-d-aspartate receptor (NMDAR) (4). KA or QA modulation of NMDAR 
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activity and glutamatergic signaling is hypothesized to contribute 
to the pathogenesis of multiple neurological disorders (5). Under 
basal conditions, kynurenine metabolism favors the formation 
of KA within the brain; however, disruptions in homeostasis 
can shift the balance toward increased production of QA. The 
rate-limiting step for the production of QA involves oxidation of 
kynurenine by kynurenine 3-monooxygenase (KMO). As KMO 
is positioned at a pivotal junction in regulating the production 
of these two metabolites, changes in KMO expression or activity 
may contribute to the development of neurodegenerative, neu-
ropsychiatric, and neurodevelopmental diseases. The purpose 
of this review is to (1) provide evidence of the critical role that 
KMO plays in maintaining the physiological balance between 
QA and KA production, (2) present examples of how this balance 
can be disrupted and associated with neurological diseases, and 
(3) demonstrate how this evidence supports KMO as a potential 
therapeutic target for neurological disorders.
Kynurenine Metabolism in the Brain
Tryptophan is metabolized to kynurenine by one of three 
rate-limiting enzymes; tryptophan 2,3-dioxygenase (TDO), 
indoleamine-2,3-dioxygenase (IDO1), or indoleamine-2,3-di-
oxygenase-like protein (IDO2). TDO expression increases in 
response to substrate levels or corticosteroid stress hormones, 
while inflammatory stimuli increase IDO1 expression (6, 7). 
Fluctuations in kynurenine metabolism have the capacity to 
indicate changes in homeostasis in the body. Under normal 
physiological conditions, local production of kynurenine within 
the brain accounts for approximately one-third of the kynurenine 
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FiGURe 1 | Schematic of kynurenine pathway metabolism. Kynurenine metabolites (inside boxes) and the enzymes that metabolize them (along arrows) are 
illustrated.
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present, while the rest is transported in from the periphery (8). 
During disease conditions, however, an even larger proportion 
of brain kynurenine originates from peripheral sources, and the 
subsequent synthesis of neuroactive kynurenine metabolites also 
increase and have the capacity to influence neurotransmitter 
systems within the brain (9).
Kynurenine
Until recently, kynurenine, itself, was considered a biologically 
inert metabolite. Kynurenine levels and the kynurenine to tryp-
tophan ratio were largely evaluated for their utility as biomarkers 
for disease. Early hypotheses suggested that increased tryptophan 
metabolism along the kynurenine pathway could reduce the bio-
availability of tryptophan for the synthesis of serotonin resulting 
in depression-associated behaviors (10). Recent clinical and 
preclinical data, within the context of inflammation, indicate 
that the brain is able to compensate for reduced peripheral 
tryptophan levels leaving central serotonin levels unaffected (11, 
12). However, identification of kynurenine as an endothelium-
derived vasodilator revealed a more relevant physiological role 
for this metabolite (13). The subsequent discovery of kynurenine 
as an endogenous ligand of the aryl hydrocarbon receptor has 
prompted intense interest into this potential receptor-mediated 
mechanism by which kynurenine could contribute directly to 
disease (14). Further, kynurenine is readily transported across 
the blood–brain barrier, and is the substrate for the synthesis of 
many metabolites that exert known neurotoxic, neuroactive, and 
oxidative actions, which have been implicated in a wide range of 
neuropathologies.
Kynurenic Acid
Under physiological conditions, most kynurenine in the brain is 
metabolized to KA (Figure 1), an NMDAR antagonist, and α7-
nicotinic acetylcholine receptor (α7nAChR)-negative allosteric 
modulator (4, 15). Peripheral KA does not cross the blood–brain 
barrier in appreciable amounts and therefore is not thought to 
contribute to central actions of KA. Kynurenine aminotransferase 
(KAT) catalyzes this reaction and is not responsive to inflamma-
tory stimuli as other kynurenine pathway enzymes are. There 
are three functional KAT isoforms, I and II the most relevant in 
mammals, and are predominantly expressed in astrocytes, giv-
ing rise to cell-type specific compartmentalization kynurenine 
metabolism (16, 17). Early studies of KA demonstrated that it can 
be neuroprotective against neuronal damage caused by neuro-
toxic QA, an effect that is most likely mediated through inhibitory 
activity at NMDARs (18). More recent studies have demonstrated 
that elevated KA can lead to disruptions in working memory, sen-
sorimotor gating, and attentional processing tasks (19–21). These 
results suggest that sustaining physiological levels of KA are likely 
important in maintaining a basal neuroprotective environment 
within the brain, but pathophysiological elevation of KA can also 
be detrimental to normal neuronal functioning.
3-Hydroxykynurenine
During inflammatory conditions and when IDO1 is upregulated, 
kynurenine metabolism shifts from the predominant production 
of KA toward the generation of increased amounts of QA. In 
the first metabolic reaction of this branch, KMO metabolizes 
kynurenine to 3-hydroxykynurenine (3-HK, Figure  1). While 
KAT enzymes are expressed in astrocytes, KMO is predominantly 
expressed in microglia, the resident immune cells in the brain 
(22). In response to inflammatory stimuli or tissue damage, 
KMO expression and 3-HK production also increase, effectively 
shuttling kynurenine metabolism toward the production of QA 
(23). Peripherally generated 3-HK is able to cross the blood–brain 
barrier by virtue of it hydrophobic nature, increasing its bioavail-
ability in the brain. 3-HK was originally thought to be a cytotoxic 
metabolite through the generation of reactive oxygen species 
(24–26). However, more recent studies have demonstrated that 
3-HK has the ability to be both antioxidant as well as pro-oxidant 
depending on the circumstances (27). In the brain, 3-HK may 
function primarily as a modulator of redox state as opposed to 
being a neurotoxic metabolite, but the direct neuropathological 
role of 3-HK remains under investigation.
3-Hydroxyanthranilic Acid
Kynureninase (KYNU) metabolizes 3-HK to 3-hydroxyan-
thranilic acid (3-HAA, Figure  1), another metabolite that is 
increased during inflammatory conditions (23). 3-HAA has been 
shown to play a role in T-cell immunity by reducing dendritic 
cell activation of T-cells and by mediating activated T-cell death 
(28, 29). Additionally, 3-HAA can induce apoptosis in monocyte-
derived cells; however, 3-HAA is also anti-inflammatory and 
neuroprotective in neuronal and glial cultures (30–32).
Quinolinic Acid
3-Hydroxyanthranilic acid dioxygenase (HAAO) metabolizes 
3-HAA into 2-amino 3-carboxymuconate 6-semialdehyde 
(ACMS, Figure 1), which undergoes a non-enzymatic conversion 
to QA (Figure 1), an endogenous NMDAR agonist (33). During 
inflammatory conditions, QA accumulates and is a major end-
point of kynurenine metabolism. With the capacity to stimulate 
excitatory glutamatergic signaling, extra-physiological concen-
trations of QA can result in neurotoxicity or neuronal death, tis-
sue lesions, and seizures (33–35). Additionally, QA neurotoxicity 
is also attributed to the generation of reactive oxygen species and 
lipid peroxidation (36–38). Due to its potent neurotoxic proper-
ties, any elevation or accumulation of QA can have detrimental 
effects on not only the local cellular environment but also can 
impact behavior as well.
Other Kynurenine Metabolites
Anthranilic Acid
Kynurenine can also be metabolized to anthranilic acid (AA, 
Figure 1) by KYNU. However, the affinity of kynurenine for this 
enzyme is very low, so metabolism only occurs to appreciable 
amounts when kynurenine concentrations are elevated (39). AA 
can also be metabolized by non-specific oxidases to generate 
3-HAA, a reaction which does appear to contribute significantly 
to the production of 3-HAA (40). AA does not increase during 
inflammatory conditions and no receptor activity for AA has 
been identified presently (23).
August 2015 | Volume 6 | Article 1164
Parrott and O’Connor Kynurenine 3-monooxygenase: an influential mediator of neuropathology
Frontiers in Psychiatry | www.frontiersin.org
Xanthurenic Acid
The transamination of 3-HK results in xanthurenic acid (XA, 
Figure 1), and this enzymatic reaction is conducted by the same 
aminotransferase (KAT) that metabolizes kynurenine to KA (41). 
Within the brain, XA appears to be functionally relevant as it is 
stored and transported within neuronal vesicles and then released 
in an activity-dependent manner (41). Further, evidence demon-
strates that XA can modulate hippocampal transmission through 
inhibition of the vesicular glutamate transporter (VGLUT) and 
was recently identified as an endogenous agonist of metabotropic 
glutamate receptors (42, 43).
Cinnabarinic Acid
Cinnabarinic acid (CA, Figure  1) is produced by the auto-
oxidation of two 3-HAA molecules in a process that also gener-
ates superoxide and hydrogen peroxide (44). Synthesis of CA 
occurs during conditions of elevated reactive oxygen species or in 
response to inflammatory stimuli (45, 46). CA is a partial agonist 
at type 4 metabotropic glutamate receptors (mGluR4), activation 
of which can protect neurons from excitotoxic death (46).
Picolinic Acid
Rather than be converted to QA, ACMS can be metabolized by 
ACMS decarboxylase (ACMSD) into 2-aminomuconate 6-semi-
aldehyde (AMS, Figure  1) that can be non-enzymatically con-
verted to picolinic acid (PA, Figure 1) (47). ACMSD expression 
is low and therefore PA formation does not represent the main 
route of metabolism of ACMS (47). PA can attenuate QA-induced 
neurotoxicity through a mechanism independent of influencing 
neuronal excitation (48).
influence of Glia on Central Kynurenine 
Metabolism
Though peripherally produced tryptophan and kynurenine con-
tribute most of the substrate for metabolism in the kynurenine 
pathway in the brain, KA and QA do not appreciably cross the 
blood–brain barrier and must be produced locally. Since the 
enzymes that subsequently direct the metabolism of kynurenine 
are preferentially expressed in separate cell types, production of 
these neuroactive metabolites is essentially compartmentalized 
within the brain and sensitive to inflammatory signals that acti-
vate microglia (Figure 2).
While most cells in the brain have the capacity to metabolize 
tryptophan to kynurenine, metabolism of kynurenine to KA 
occurs mainly in astrocytes, and the production of QA occurs 
mainly in activated microglia (22, 49). Under basal conditions 
in the brain, kynurenine is predominantly metabolized to KA in 
astrocytes, cells that primarily function to maintain homeostasis 
within the brain (16). However, during neuroinflammatory con-
ditions, kynurenine metabolism shifts to generating neurotoxic 
QA and microglia become the primary cellular mediators (23). 
Neuroinflammation includes the propagation of inflammatory 
signals and the activation of the resident immune cells in the 
brain, microglia. Shifting the metabolism of kynurenine from 
astrocytes toward activated microglia during neuroinflamma-
tion corresponds with the alteration in production of KA to QA 
(i.e., increasing the QA to KA ratio). While astrocytes have the 
capability to clear extracellular QA and metabolize it to nicotinic 
acid, they are not able to produce it (22). Further, during neuro-
inflammatory conditions, the capacity of astrocytes to clear QA 
may be impaired (50). In disease states, microglia can remain 
active and neuroinflammation can persist, possibly resulting in 
production and accumulation of neurotoxic kynurenine metabo-
lites. Compartmentalization provides a mechanism to effectively 
and physically separate the two distinct branches of kynurenine 
metabolism.
KMO is Positioned at an influential 
Regulatory Point in the Kynurenine 
Pathway
Multiple kynurenine metabolites have the capacity to directly 
or indirectly influence neuronal processes, both in a beneficial 
or detrimental manner. However, those with potentially the 
greatest impact are KA and QA as they can influence excitatory 
glutamatergic signaling by binding the NMDAR. Many neuro-
logical disorders are hypothesized to involve disrupted glutamate 
signaling, and therefore, modulation of KA or QA production 
could provide a more relevant therapeutic target (5). During neu-
roinflammatory conditions, KMO is the principle regulator of the 
metabolic fate of kynurenine to either KA or QA, and as such, it 
could be a prominent mediator of neuropathology development 
(Figure 2).
KMO Regulates Quinolinic Acid Production
Kynurenine 3-monooxygenase metabolism of kynurenine 
increases in response to elevated substrate levels and upregulation 
in KMO expression, both associated with neuroinflammation, 
typically characterized by microglia activation, and the propa-
gation of central inflammatory signals. Metabolism continues 
along the KMO-dependent branch of the pathway producing 
3-HK, 3-HAA, and QA, contributing neurotoxic metabolites to 
this environment of neuroinflammation (23, 51). Though the 
acute process is typically adaptive, prolonged neuroinflamma-
tion or the presence of secondary factors that can exacerbate 
the neuroinflammatory response (i.e., gene polymorphisms, 
comorbidity, etc.) often results in maladaptive consequences on 
normal neuronal functioning (52, 53). Numerous neurological 
disorders are characterized by chronic inflammation, and their 
pathology is often associated with microglia activation (54). 
Consequently, continued neuroimmune stimulation can also 
result in the production of neurotoxic kynurenine metabolites, 
3-HK and QA, that generate reactive oxygen species and increase 
the potential for glutamate excitotoxicity. In vivo administration 
of 3-HK induces tissue damage that is only attenuated when co-
treated with N-acetyl-l-cysteine, an antioxidant, not MK-801, an 
NMDAR antagonist (55). In vitro studies have further demon-
strated that 3-HK can cause neuronal cell death that is susceptible 
to glutathione, catalase, and desferrioxamine, antioxidants that 
demonstrate 3-HK confers its cellular toxicity via the generation 
of oxidative stress (24–26). However, contradictory studies also 
demonstrate that 3-HK can reduce markers of oxidative stress, 
specifically in C6 glioma cells, and protects B-phycoerythrin 
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FiGURe 2 | KMO regulation of kynurenine metabolism. (Left panel) KMO 
upregulation during neuroinflammation results in a shift in kynurenine 
metabolism that increases production of QA in microglia. This change in 
metabolism is associated with elevated oxidative stress and glutamate 
excitotoxicity that could contribute to Huntington’s disease (HD), Alzheimer’s 
disease (AD), and even depression. (Right panel) KMO dysfunction as a 
consequence of genetic mutation favors the production of KA in astrocytes, 
which is accompanied by disruptions in cognitive performance and psychosis. 
KA elevations and KMO polymorphisms have been associated with bipolar 
disorder (BPD), schizophrenia (SCZ), and some neurodevelopmental disorders. 
KMO has the potential to regulate the production of both QA and KA thereby 
contributing to the development of multiple neurological disorders.
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from peroxyl radical-mediated oxidative damage (56, 57). 
Despite this evidence, the potential for 3-HK to contribute to 
oxidative stress and neuronal damage, particularly contributing 
to disease progression, still remains, as elevated 3-HK levels 
have been described in neurodegenerative and neuropsychiatric 
disorders (58).
Quinolinic acid can also induce oxidative damage, specifically 
lipid peroxidation, which is attenuated by pretreatment with KA 
or MK-801 (36, 59). Lipid peroxidation produced by QA can also 
be attenuated by antioxidants, demonstrating that both free radi-
cal formation and NMDAR activation contribute to QA-induced 
oxidative damage (60, 61). As microglia remain activated and 
continue metabolizing kynurenine, QA production similarly 
increases and is released into the synapse (62). The breakdown of 
QA by quinolinic acid phosphoribosyl transferase (QPRT) occurs 
much slower than the production, therefore QA can rapidly 
accumulate (63, 64). Elevated QA activates NMDARs, stimulates 
glutamate release, and prevents glutamate re-uptake by astrocytes 
(65). As extracellular glutamate concentrations rise from contin-
ued release and re-uptake inhibition, the neurons in the synapse 
can undergo cytotoxic cell death (66). Direct administration of 
QA is a potent inducer of seizures, a behavioral phenotype of 
neuronal over-excitation (67). As KA can experimentally attenu-
ate QA excitotoxicity and oxidative damage, the existence of this 
endogenous antagonism suggests that maintenance of metabolic 
homeostasis within the brain is important, and, as might be 
predicted, disruption of metabolic balance could contribute to the 
underlying pathology of many brain-based diseases. In disorders 
associated with inflammation and microglia activation, increased 
KMO-dependent kynurenine metabolism would result in 3-HK 
and QA accumulation, while a disruption of KMO activity 
would favor a metabolic shift toward the production of KA. The 
accumulation in neurotoxic metabolites could in turn contribute 
oxidative stress and neuronal excitotoxicity. KMO therefore 
represents a viable therapeutic target for a number of diseases 
associated with neuroinflammation and neurodegeneration.
KMO Regulates Kynurenic Acid Production
Under physiological circumstances in the brain, a majority of 
kynurenine is metabolized by KATs to KA, predominantly in 
astrocytes (49). As KA is an inhibitor of the NMDAR, it was 
initially thought to be neuroprotective by attenuating over-excita-
tion of glutamatergic neurons (4). Multiple studies demonstrated 
that as the endogenous antagonist to QA, KA could counteract 
the damaging and neurotoxic effects of elevations in QA in vivo 
specifically through the NMDAR (4, 18, 68, 69). KA also inter-
acts with the mesocorticolimbic dopamine (DA) area through 
its antagonism of the NDMAR and therefore has the potential 
to impact disorders associated with this system (70–72). The 
inhibitory actions of KA on cholinergic transmission through the 
α7nAChR also indirectly influence the regulation of multiple neu-
rotransmitter systems including both GABA and DA signaling 
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in the striatum (73, 74). Despite the seemingly positive impact 
KA has on neuronal systems, the beneficial effects of elevated KA 
only extend so far, as pathophysiological levels have been found 
to be detrimental. Endogenous central KA can be increased by 
peripheral administration of kynurenine to rodents and has 
resulted in disruptions in cognitive performance. Specifically, 
elevations in KA impair sensorimotor gating, attentional pro-
cessing of environmental stimuli, spatial working memory, and 
contextual learning memory (19–21, 75). These behavioral tasks 
have relevance in neuropsychiatric diseases, such as schizophre-
nia (SCZ) and bipolar disorder (BPD), characterized by cognitive 
disruptions and psychosis (76). Though KA can be increased 
experimentally by administration of kynurenine, recently 
characterized KMO polymorphisms in the human populations 
provide a clinical context for elevations in KA contributing to 
pathophysiology. These genetic alterations in KMO are associated 
with decreased gene expression and increased KA concentrations 
in patients suffering from SCZ and BPD (77–80). Together, these 
data support the notion that deviation of kynurenine metabolic 
balance too far in either direction may contribute to impaired 
brain function.
Neurological Disorders and Disrupted 
Kynurenine Metabolism
Consequences of a persistent imbalance in kynurenine 
metabolism can be demonstrated experimentally; however, the 
relevance of kynurenine metabolites to disease pathogenesis has 
been suggested in several neurological disease contexts, based 
on patient post-mortem tissue, plasma, and cerebrospinal fluid 
(CSF) sampling studies. Determination of kynurenine metabolite 
concentrations in patients diagnosed with neurological disorders 
allows for more direct correlations between metabolite meas-
ures, pathology development, and symptoms. Moreover, pre-
clinical modeling allows for further exploration into the potential 
mechanism(s) that might connect kynurenine metabolism and 
disease pathogenesis. Kynurenine metabolic balance in relevant 
neurodegenerative, neuropsychiatric, and neurodevelopmental 
disorders is reviewed below (for summary see Table 1).
Huntington’s Disease
Huntington’s disease (HD) is a severe neurodegenerative disorder 
that is characterized by motor, cognitive, and neuropsychiatric 
symptoms. Early experimental models demonstrated that gluta-
mate-mediated excitotoxicity in the basal ganglia could mirror 
the neuronal degeneration seen in HD patients (129). Therefore, 
it is possible that elevated levels of QA, which can cause excito-
toxicity could contribute to the pathogenesis of HD. Though early 
attempts to measure QA in post-mortem cortical tissue indicated 
no difference between HD patients and controls, later studies 
demonstrated that both KA and 3-HK were elevated suggesting 
an overall increase in kynurenine metabolism (Table 1) (81, 84, 
87, 88). More specifically, it was later established that both QA and 
3-HK are increased in striatal and cortical regions during the early 
stages of HD (Grade 0/1), suggesting temporal specificity for the 
disruption in kynurenine metabolism (Table 1) (89). Further, HD 
patients present with elevated markers of oxidative stress, which 
can be propagated by 3-HK and QA supporting the hypothesis 
that these metabolites can contribute to HD pathogenesis (130, 
131). The YAC128, R6/2, HdhQ92/HdhQ111, and FBV/N mutant HD 
mouse models all have endogenous disruptions in the kynurenine 
pathway that result an increase in neurotoxic metabolites that 
accumulate as the mice age (Table 1) (88, 90, 93). These mutant 
HD mouse models demonstrate that the development of HD-like 
pathology can parallel changes in kynurenine metabolism. As the 
enzyme upstream of the synthesis of both 3-HK and QA, KMO is 
a relevant potential therapeutic target for the modulation of this 
imbalance in kynurenine metabolites. Interestingly, inhibition 
of KMO ameliorates HD-associated neurodegeneration both in 
a Drosophila melanogaster HD fly model (Htt93Q) and in the 
R6/2 mutant HD mouse model (92, 100). Taken together, the 
data from patient analyses and preclinical studies demonstrate 
that HD is associated with elevated neurotoxic kynurenine 
metabolites, 3-HK and QA, and targeting KMO to repair this 
disease-associated imbalance has therapeutic promise in treating 
neurodegeneration.
Huntington’s disease is also considered to be an inflammatory 
disease as elevations in plasma inflammatory markers have been 
described both in patients and in a HD-mutant mouse model 
(132). This peripheral response most likely is a mirror of the 
neuroinflammatory response accompanying disease progression 
(133, 134). Neuroinflammation in HD has mainly been charac-
terized by microglia activation particularly associated with the 
brain regions of greatest neurodegeneration (135, 136). Indeed, 
an imaging study demonstrated that in HD pre-symptomatic 
gene carriers, microglia activation was already elevated and it 
correlated with regions undergoing neurodegeneration (137). 
The R6/2 mutant HD mouse model also exhibits neuroinflamma-
tion and microglia activation associated with HD-like pathology 
development (138). Microglia are likely involved in the pathogen-
esis of HD and produce neurotoxic 3-HK and QA when activated 
providing a clear link between disrupted kynurenine metabolism 
and HD-associated pathology development.
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia 
and is a serious neurodegenerative disorder defined by a dramatic 
decline in cognitive function. Though AD pathology is character-
ized by amyloid-β plaque and hyper-phosphorylated tau neurofi-
brillary tangle accumulation, the pathogenesis of this disease is 
still not fully understood (139). Early analysis of post-mortem 
brain samples from AD patients failed to reveal an increase in 
kynurenine metabolism (Table  1) (86, 87, 95). Even so, more 
recent assessments of peripheral kynurenine metabolites in AD 
patients have indicated that serum 3-HK and QA concentrations 
were elevated while the KA concentration decreased (Table 1) 
(98, 99, 101). Further, one study specifically demonstrated that 
serum QA concentration was inversely correlated with cognitive 
performance in AD patients (99). Kynurenine pathway activa-
tion and production of neurotoxic metabolites have also been 
characterized in association with AD pathology. Both IDO1 
and QA were increased in AD post-mortem hippocampal tissue 
specifically associated with the perimeter of amyloid-β plaques 
(140). As the accumulation of plaques and tangles results in 
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TABLe 1 | Neurological diseases with disrupted kynurenine metabolism – a focus on KMO regulated metabolites.
Disease Species Observation Reference
Huntington’s disease 
(HD)
Human ↑ KA (post-mortem brain, motor cortex) (81)
Human (n.d.) QA (post-mortem brain, putamen, or frontal cortex) (82)
Human (n.d.) QA (cerebrospinal fluid) (83)
Human ↑ 3-HK (post-mortem brain, frontal and temporal cortex) (84)
Human ↑ Kynurenine/KA Ratio (post-mortem brain, putamen) (85)
↓ KA (cerebrospinal fluid)
Human ↓ KA (post-mortem brain, five cortical regions) (86)
↓ 3-HK (post-mortem brain, inferior temporal gyrus)
Human ↓ KA (cerebrospinal fluid) (5)
(n.d.) QA (cerebrospinal fluid)
Human ↑ 3-HK (post-mortem brain, frontal and temporal cortex, putamen) (87)
Human ↑ KA (post-mortem brain, cerebral cortex) (88)
↑ 3-HK (post-mortem brain, cerebral cortex, and striatum)
FBV/N mice ↑ KA (brain, cortex, and striatum) (88)
↑ 3-HK (brain, cortex, and striatum) 
Human ↑ 3-HK (Grade 0/1 post-mortem brain, striatum, and frontal cortex) (89)
↑ QA (Grade 0/1 post-mortem brain, striatum, and frontal cortex) 
(n.d.) 3-HK (Grade 2–4 post-mortem brain, striatum, or frontal cortex) 
(n.d.) QA (Grade 2–4 post-mortem brain, striatum, or frontal cortex) 
(n.d.) KA (Grade 0–4 post-mortem brain, striatum, or frontal cortex)
R6/2 mice ↑ 3-HK with age (brain, cortex, striatum, and cerebellum) (90)
(n.d.) QA with age (brain, cortex, striatum and cerebellum)
(n.d.) KA (brain, cortex, striatum, and cerebellum)
HdhQ92 and 
HdhQ111 mice
↑ 3-HK (15–17 mo. brain, cortex, striatum, and cerebellum) (90)
↑ QA (15–17 mo. brain, cortex, and striatum)
(n.d.) KA (brain, cortex, striatum, or cerebellum)
YAC128 mice ↑ 3-HK with age (brain, cortex, striatum, and cerebellum) (90)
↑ QA with age (brain, cortex, and striatum)
(n.d.) KA (brain, cortex, striatum, or cerebellum)
R6/2 mice ↑ KMO activity with age (brain, cortex) (91)
Htt93Q flies ↑ 3-HK/KA ratio (fly heads) (92)
YAC128 mice ↓ 3-HK (3 mo. brain, striatum) (93)
↓ QA (3 mo. brain, cerebellum)
↑ 3-HK (12 mo. brain, striatum)
↑ QA (12 mo. brain, cerebellum)
Alzheimer’s disease 
(AD)
Human (n.d.) QA (post-mortem brain, frontal, temporal, or parietal cortex) (94)
Human (n.d.) QA (post-mortem brain, six cortical regions, hippocampus, or caudate) (95)
(n.d.) QA (cerebrospinal fluid)
Human (n.d.) KA (post-mortem brain, four cortical regions, or caudate) (86)
(n.d.) 3-HK (post-mortem brain, inferior and middle temporal gyrus, or caudate)
Human ↓ KA (cerebrospinal fluid) (5)
(n.d.) QA (cerebrospinal fluid)
Human (n.d.) 3-HK (post-mortem brain, temporal cortex) (87)
Human ↓ 3-HK (cerebrospinal fluid) (96)
Human ↑ KA (post-mortem brain, putamen and caudate nucleus) (97)
(n.d.) KA (post-mortem brain, frontal cortex, hippocampus, or cerebellum)
(n.d.) 3-HK (post-mortem brain, frontal cortex, hippocampus, cerebellum, putamen, or caudate nucleus)
Human ↓ KA (serum and red blood cells) (98)
Human ↓ KA (serum) (99)
↑ QA (serum)
APPtg mice ↑ KA (6 mo. brain, cortex) (100)
(n.d.) 3-HK (6 mo. brain, cortex)
(n.d.) QA (6 mo. brain, cortex)
Human ↑ 3-HK (serum) (101)
(n.d.) KA (serum)
(n.d.) QA (serum)
Depression Human (n.d.) KA (urinary excretions following tryptophan loading) (102)
(n.d.) 3-HK (urinary excretions following tryptophan loading)
Human ↓ KA (serum) (103)
Human ↑ QA (cerebrospinal fluid) (104)
↑ QA (cerebrospinal fluid, suicide attempters)
(n.d.) KA (cerebrospinal fluid, suicide attempters)
(Continued)
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Disease Species Observation Reference
Human ↑ QA (cerebrospinal fluid, following suicide attempt) (105)
↓ KA (cerebrospinal fluid, following suicide attempt)
Human (n.d.) KA (serum) (106)
(n.d.) QA (serum)
Human (n.d.) KA (serum) (107)
(n.d.) 3-HK (serum)
(n.d.) QA (serum)
Human ↓ KA/QA ratio (serum) (108)
(n.d.) KA (serum)
(n.d.) 3-HK (serum)
(n.d.) QA (serum)
Inflammation-
associated 
depression
Human ↑ Kynurenine/KA ratio (interferon-α treatment, serum) (109)
Human ↓ KA (interferon-α treatment, serum) (110)
Human ↑ KA (interferon-α treatment, cerebrospinal fluid) (12)
↑ QA (interferon-α treatment, cerebrospinal fluid)
(n.d.) QA (interferon-α treatment, plasma)
C57BL/6J mice ↑ 3-HK [lipopolysaccharide (1 mg/kg), brain] (23)
↑ QA [lipopolysaccharide (1 mg/kg), brain]
(n.d.) KA [lipopolysaccharide (1 mg/kg), brain]
Bipolar disorder 
(BPD)
Human (n.d.) KA (post-mortem brain, anterior cingulate) (111)
Human ↓ KA (serum) (112)
Human ↑ KA (cerebrospinal fluid) (113)
Human ↑ KA (cerebrospinal fluid, with history of psychotic features) (114)
Human ↑ KA (cultured fibroblasts) (115)
↑ 3-HK (cultured fibroblasts)
Human ↑ KA [cerebrospinal fluid, with KMO Arg(452) mutant allele] (80)
↓ KMO expression [post-mortem brain, with KMO Arg(452) mutant allele, hippocampus]
Human ↓ KA/QA ratio (serum) (116)
(n.d.) KA (serum)
(n.d.) 3-HK (serum)
(n.d.) QA (serum)
Schizophrenia (SCZ) Human (n.d.) QA (cerebrospinal fluid) (83)
Human ↑ KA (post-mortem brain, dorsolateral prefrontal cortex) (117)
(n.d.) KA (post-mortem brain, frontopolar area, or tertiary visual association cortex) 
(n.d.) 3-HK (post-mortem brain, dorsolateral prefrontal cortex, frontopolar area, or tertiary visual  
association cortex)
Human ↑ KA (cerebrospinal fluid) (118)
Human (n.d.) 3-HK (serum) (119, 120)
Human ↓ KA (serum) (121)
↑ 3-HK (serum)
Human ↑ KA (post-mortem brain, frontopolar area) (122)
(n.d.) KA (post-mortem brain, dorsolateral prefrontal cortex)
↓ KMO activity (post-mortem brain, dorsolateral prefrontal cortex, and frontopolar area)
Human ↑ KA (cerebrospinal fluid, with KMO rs1053230 single nucleotide polymorphism) (79)
Human ↑ KA (cerebrospinal fluid) (123)
Human ↓ KA (cerebrospinal fluid, following suicide attempt) (124)
Human ↑ KA (cultured fibroblasts) (115)
↑ 3-HK (cultured fibroblasts)
Human ↑ KA (cerebrospinal fluid) (125)
(n.d.) QA (cerebrospinal fluid)
↓ QA/KA ratio (cerebrospinal fluid)
Neurodevelopmental 
disorders
Human ↑ KA (Down syndrome, post-mortem brain, frontal cortex) (126)
(n.d.) KA (Down syndrome, post-mortem brain, temporal cortex)
BTBR T+tf/J 
mice
KMO single nucleotide polymorphisms (3, autism spectrum disorder behavioral model) (127)
Human (n.d.) KA (ADHD, serum) (128)
(n.d.) 3-HK (ADHD, serum)
Disruptions in kynurenine metabolites are described in Huntington’s disease (HD), Alzheimer’s disease (AD), depression, bipolar disorder (BPD), schizophrenia (SCZ), and 
neurodevelopmental disorders. Only three kynurenine metabolites, 3-HK, KA, and QA, were included in this table as they demonstrate potential changes in KMO activity that could 
result in neuropathological consequences. Only animal studies with endogenous model disease disruptions were incorporated in the table (i.e., genetic mutant model).
(n.d.), no difference between disorder/mutant animal samples and healthy control/control animal samples.
TABLe 1 | Continued
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microglial activation and neuroinflammation, it is feasible that 
this stimulates kynurenine metabolism and neurotoxic metabo-
lite production in AD (141). In  vitro, Aβ-42, the neurotoxic 
constituent of amyloid-β plaques, can induce IDO1 upregulation 
and QA production in human macrophages and microglia (142). 
Elevated neurotoxic kynurenine metabolite production arising 
from microglia activation may in turn contribute to the patho-
genesis of AD. As in HD, increased extracellular glutamate and 
neuronal excitotoxicity are thought to contribute to the degen-
eration of neurons as AD pathology accumulates (143, 144). AD 
patients also have elevated markers of oxidative stress, both of 
which an elevation in neurotoxic QA and 3-HK can propagate 
(145). Specifically, QA has been shown to prompt tau phospho-
rylation in  vitro indicating that it may have a direct influence 
on development of AD-associated pathology (146). These data 
provide evidence that inflammation associated with markers of 
AD pathology may upregulate kynurenine metabolism and the 
production of neurotoxic metabolites. Though directly focusing 
on inflammation therapeutically has had little success in AD 
patients, targeting the kynurenine pathway, further downstream 
still remains a viable option. In the APPtg AD mouse model, 
peripheral inhibition of KMO attenuated spatial memory loss 
and synapse loss associated with an increase in brain KA (100). 
These data demonstrate that KMO could provide a treatment 
focus in AD with the intent of preventing neurotoxic metabolite 
accumulation.
Alzheimer’s disease is associated with the development and 
propagation of neuroinflammation in response to the accu-
mulation of amyloid-β plaques and tau tangles. Post-mortem 
analyses have revealed that both microglia and astrocytes 
become upregulated and activated as AD-associated neuropa-
thology develops (141, 147). One imaging study demonstrated 
that microglia activation is specifically correlated with cognitive 
status, which could not be predicted by amyloid-β load (148). 
Transgenic mouse models that develop AD-related neuropathol-
ogy also exhibit microgliosis and astrocytosis associated with 
the advancement of pathology (149, 150). These data further 
demonstrate the significance of microglia to AD pathology 
and the relevance of neurotoxic kynurenine metabolites to the 
progression of AD.
Depression
Depression is a highly debilitating neuropsychiatric disorder with 
a diverse symptom profile, including depressed mood, anxiety, 
anhedonia, fatigue, and cognitive impairment. Unfortunately, less 
than half of affected individuals experience satisfactory therapeu-
tic benefit from typical antidepressant treatments (151). Studies 
describing kynurenine metabolism in patients with depression 
report increases in CSF QA and decreases in plasma KA and the 
KA/QA ratio (Table 1) (103, 104, 108). Despite these data, other 
studies report no difference in kynurenine metabolism between 
patients with depression and controls (Table  1) (106, 107). 
Analysis of kynurenine metabolites in patients with depression 
who had also attempted suicide revealed an elevation in CSF QA 
and a decrease in KA (Table 1) (104, 105). These results suggest 
a role for altered kynurenine metabolism in the pathogenesis 
of depression, and additional studies have demonstrated that 
inflammation can induce both depression symptoms and meta-
bolic changes. Specifically, interferon-α therapy, used to treat 
hepatitis C, increases the prevalence of depression symptoms in 
the patients receiving treatment, and the severity of symptoms 
are correlated with elevations in CSF QA (12, 109). It was recently 
proposed that kynurenine pathway enzyme expression could be 
a valid etiological classification system for patients diagnosed 
with depression (152). As inflammation-induced alterations in 
the kynurenine pathway represents a significant gene by environ-
ment interaction, such a classification system could potentially 
provide a more precise way to treat patients, both genetically and 
pharmacologically.
Inflammation is hypothesized to be a major contributor to the 
pathogenesis of depression and clinically, administration of endo-
toxin can directly precipitate depression symptoms (153, 154). 
Further, patients who suffer from chronic inflammatory diseases 
are significantly more likely to develop symptoms of depression 
than healthy adults (155). While direct clinical evidence in 
patients of depression that inflammation activates microglia and 
upregulates KMO within the brain is lacking, it is feasible that 
inflammation induces an imbalance in kynurenine metabolism 
elevating neurotoxic QA production that results in depression-
related symptoms (10, 156). Preclinically, inflammatory stimuli 
induce depressive-like behaviors that are dependent on increased 
kynurenine production by IDO1, demonstrating that kynurenine 
metabolism is necessary for inflammation-related behaviors (11, 
157–160). Our lab recently demonstrated that KMO-deficient 
mice were protected from inflammation-induced deficits in 
recognition memory, a depressive-like behavior (160). These 
data provide preliminary evidence that inflammation-induced 
depressive-like behaviors are specifically dependent on neuro-
toxic kynurenine metabolism. A recent study demonstrated that 
lipopolysaccharide (LPS)-induced depressive-like behaviors can 
be attenuated with administration of the NMDAR antagonist 
ketamine, and LPS treatment induces accumulation of central 
3-HK and QA (23). These results indicate that inflammation-
induced depressive-like behavioral changes are in part mediated 
by NMDAR activation, which could potentially be accomplished 
by the elevation in QA, an NMDAR agonist. Inflammatory stimuli 
can undoubtedly alter kynurenine metabolism favoring neuro-
toxic metabolism through KMO, which appears to contribute to 
the mechanism by which inflammation results in depression and 
related behaviors.
Though post-mortem samples from patients with depression 
have been analyzed for microglia activation, the results from 
multiple studies are inconsistent (161, 162). They generally 
favor elevated microglia activation in patients with depression 
and a significant increase in activation in patients who also 
committed suicide (163). Preclinically, inflammatory stimuli 
can induce depressive-like behaviors that are associated with 
a neuroinflammatory response including microglia activation 
(164). Minocycline, a microglial activation inhibitor, has been 
demonstrated to attenuate inflammation-induced depressive-
like behaviors (165). Together, these data strongly suggest that 
microglia could potentially be involved in the pathogenesis of 
depression behaviors that are associated with inflammation and 
altered kynurenine metabolism.
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Bipolar Disorder
BPD is defined by alternating periods of mania, which often 
features psychosis, and depression interspersed with symptom-
free intervals, known as euthymia (166). Further, cognitive 
impairments such as those in executive functioning and verbal 
memory are present in all states of BPD (167). During the 
euthymic phase of patients with BPD, the concentration of 
CSF KA was found to be significantly elevated (Table 1) (113). 
Specifically, higher levels of CSF KA were correlated with a his-
tory of psychosis or having experienced a recent manic episode 
in BPD patients (Table 1) (114). Acute psychotic symptoms in 
HIV-1-infected patients were also associated with elevations in 
CSF KA, further confirming the significance of alterations in 
KA concentration on the development of psychosis behavior 
(168). Dysregulation in the DA system is thought to be one of 
the mechanisms responsible for BPD symptomology, therefore 
it is possible that KA influences psychosis through its interac-
tion with DA (169, 170). Analysis of the KMO Arg(452) mutant 
allele in BPD patients, which reduces KMO expression and 
increases KA production, also revealed an association with psy-
chotic symptoms during manic episodes (Table 1) (80). These 
are further data to support the role of KMO in the production of 
KA and the influence of KA concentration on psychosis in BPD.
Another mechanism thought to contribute to the patho-
genesis of BPD is immune activation, specifically through the 
production of pro-inflammatory cytokines (171, 172). Recent 
data points to an explicit role for IL-1β as CSF concentrations 
were increased in euthymic BPD patients compared to controls 
and were correlated with a recent history of at least one manic 
episode (173). Associated with this inflammatory paradigm, a 
recent study found that the serum KA/QA ratio was decreased 
in BPD patients contrary to previous studies demonstrating 
an elevation in KA (Table 1) (116). Further, isolation of BPD 
patient skin fibroblasts demonstrated increased baseline pro-
duction of both KA and 3-HK, however, pro-inflammatory 
cytokine stimulation only resulted in elevated 3-HK accumu-
lation (115). In accord with this hypothesis, elevated neuroin-
flammatory markers and glia cell (microglia and astrocytes) 
activation have been described in post-mortem BPD patient 
tissue samples (174, 175). Neuroinflammation in BPD patients 
would propagate the production of neurotoxic kynurenine 
metabolites similar to those that have already been described 
in patients. Though studies may support alternate activation 
of these two branches of metabolism in BPD, it is clear that 
there is a disruption that could be therapeutically targeted 
by focusing on altering kynurenine metabolism at KMO in 
microglia.
Schizophrenia
SCZ is a neuropsychiatric disorder defined by positive symptoms 
(psychosis and paranoia), negative symptoms (social deficits 
and anhedonia), and cognitive dysfunction. The mechanisms 
underlying the pathogenesis of SCZ are not well understood. 
Currently, it is believed that SCZ results from neurocircuit-level 
disruptions in neurotransmitters including dysfunction in DA 
and glutamate systems (176). Post-mortem tissue analysis of 
SCZ patients revealed an increase in KA that was associated 
with decreased KMO activity rather than alterations in KAT 
activity (Table  1) (117, 122). CSF KA concentration was also 
elevated in SCZ patients while there was no change in CSF QA 
concentration (Table 1) (118, 123, 125). Interestingly, CSF KA 
was significantly decreased in SCZ patients who attempted 
suicide compared to non-attempters (Table  1) (124). Studies 
that were conducted to determine the correlation between 
KMO gene polymorphisms and SCZ diagnosis did not reveal 
any significant relationships (77, 177). However, one KMO 
polymorphism that potentially impacts substrate interaction, 
rs1053230, correlated with elevated CSF KA concentrations in 
SCZ patients, further demonstrating the link between KMO 
and disrupted kynurenine metabolism (Table  1) (79). Studies 
have demonstrated that KA can disrupt cognitive performance 
through its interaction with the glutamate system and it has the 
potential to contribute to psychotic symptoms by influencing 
DA signaling. Preclinically, reducing endogenous levels of KA 
can prevent amphetamine- and ketamine-induced disruptions 
in sustained attention, working memory, and spatial memory 
tasks, paradigms used to experimentally model SCZ deficits 
(178). Together, these data provide justification for better 
understanding the impact of disrupted kynurenine metabolism 
on SCZ pathogenesis and the potential relevance of targeting 
KMO therapeutically in SCZ.
While the potential for the involvement of inflammation and 
pro-inflammatory cytokines in the pathogenesis of SCZ exists, 
the data analyzing the supporting neuropathological evidence 
are inconsistent. Initial examination of SCZ post-mortem tissue 
indicated a reduction in density of astrocyte markers (GFAP) 
when compared to normal controls (179). More recent SCZ 
post-mortem tissue investigations have revealed upregula-
tion of both microglia and astrocyte markers (180–182). 
An additional binding analysis revealed that QA-specific 
microglia were reduced in SCZ, but overall microglia density 
was unchanged (183). A recent imaging study in SCZ patients 
found no difference in microglia activation in white or gray 
matter, contradicting the multiple post-mortem studies (184). 
Despite these varying results, it is clear that there is potential for 
a pathological role of neuroinflammation and glia involvement 
in SCZ (185).
Neurodevelopment
Brain development and maturation is a dynamic process 
that begins in the embryo and continues well into the young 
adult years (186). However, neurodevelopment appears to be 
quite susceptible to disruptions in kynurenine metabolism. 
Kynurenine supplemented chow fed to gestating mothers pre-
natally and offspring postnatally elevates KA in adolescences 
and adults (187, 188). Exogenous kynurenine treatment during 
these periods also results in disruptions in contextual memory, 
spatial working memory, and cognitive flexibility in adults 
(187–190). Specifically, elevating KA with kynurenine during a 
prenatal period decreases dendritic spine density and markers of 
excitatory transmission (evoked glutamate release and mGluR2 
receptor expression) (190). Kynurenine metabolism during 
neurodevelopment was also targeted by administering a KMO 
inhibitor to pregnant dams in late gestation, which results in an 
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immediate increase in KA in the embryo (191). In adolescence, 
this treatment results in an increase in neuronal excitability, an 
increase in GluN2A/2B subunits of the NMDAR and elevated 
PSD95, a post-synaptic density marker (191). Adults also show 
changes in excitability, decreases in dendritic complexity and 
number, disruptions in long-term potentiation, and increased 
neurogenesis (192–194). These results clearly demonstrate 
that alterations in kynurenine metabolism occurring during 
development can significantly impact normal neuronal func-
tioning in adolescence and continue into adulthood. The BTBR 
T+tf/J spontaneous mutant mouse has been used preclinically 
to model behaviors of autism spectrum disorder (ASD), one 
neurodevelopmental disorder (195). The BTBR mouse model is 
characterized by repetitive behaviors, communication deficits, 
and social deficits that are also associated with three KMO 
polymorphisms specific to the BTBR strain (127). This correla-
tion suggests that in the BTBR mouse model, a disruption in 
KMO function may contribute to the development of ASD-like 
behavior. Though there are only a couple of studies analyzing 
kynurenine metabolite disruptions in the context of neurode-
velopmental disorders (see Table 1), the strong preclinical data 
supports the importance of KMO and its regulation in proper 
development.
Immune activation, either in pregnant mothers or in early 
development, provides a more clinically relevant model for 
determining the impact of disrupted kynurenine metabolism 
during neurodevelopment. Preclinical maternal immune 
activation (MIA) is modeled by administration of Poly I:C, an 
immune mimetic, to pregnant dams, which results in disruptions 
in sensorimotor gating and spontaneous locomotor activity in 
adult offspring (196, 197). There are also significant increases 
in microglia activation in the offspring of MIA dams (197, 198). 
When neonatal pups are given an immune stimulus (Poly I:C, 
influenza, LPS), this also results in disturbances in adulthood 
including impaired sensorimotor gating and working memory 
concurrent with elevated microglia activation (199–201). Though 
these models demonstrate the association of microglia activation 
with behaviors that result from impaired neurodevelopment, 
few studies have directly characterized microglia activation in 
patients with neurodevelopmental disorders. A recent imaging 
study established that young adults diagnosed with ASD have sig-
nificantly elevated microglia activation in multiple brain regions 
(202). These data further support the possibility that microglia 
contribute to neurodevelopmental disorders, both during devel-
opment and throughout maturation.
Conclusion/Future Research
Kynurenine metabolites have the capacity to directly or indi-
rectly affect neuronal functioning under both basal and during 
 pathological conditions. Though evidence suggests that multiple 
neurological disorders are associated with disruptions in central 
kynurenine metabolism (Table  1), it is unclear whether these 
changes occur during disease progression or contribute directly 
to disease initiation. Determination of the specific impact that 
disruptions in kynurenine metabolism have on the pathogenesis 
of neurological disorders will allow for better understanding of 
individual diseases and provide an additional therapeutic objec-
tive. Preclinical evidence demonstrates that neurotoxic QA and 
inhibitory KA can both be detrimental physiologically and behav-
iorally when levels become elevated. Therefore, with the capacity to 
direct kynurenine metabolism to both QA and KA, KMO provides 
a potential target for treatment intervention. While the ability to 
modulate KMO activity would be a powerful tool to determine 
if targeting it therapeutically is feasible, few techniques currently 
exist with therapeutic potential. Until recently, KMO pharmaco-
logical inhibitors were limited modulating kynurenine metabolism 
to the periphery as they did not cross the blood–brain barrier (9). 
However, a newly described competitive inhibitor was demon-
strated preclinically to have the ability to inhibit KMO peripherally 
and partially penetrate the blood–brain barrier (203). Though 
proposed for therapeutic use in HD patients, the data reviewed 
here clearly demonstrate that treatment with an effective KMO 
inhibitor could potentially be beneficial to patients diagnosed 
with other neurological disorders. Additionally, KMO-deficient 
mice have biochemically characterized providing a valuable pre-
clinical research tool to further explore the biological and patho-
physiological role of KMO (204). Whether disrupted kynurenine 
metabolism is a biomarker of disease risk or a treatment target 
for slowing the disease progression, it is clear that the kynurenine 
pathway is clinically relevant to neurological disorders. Therefore, 
it is necessary to understand the significance of maintaining the 
balance between KA and QA production through KMO, both in 
health and neurological diseases.
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